<DOC>
	<DOCNO>NCT00348153</DOCNO>
	<brief_summary>TNF alpha Inhibitors effective treat rheumatologic disease well uveitis . Adalimumab first member new class TNF antibody compound developed contain exclusively human sequence . We want test efficacy safety TNF alpha Inhibitor Adalimumab patient active uveitis despite standard immunosuppressive therapy .</brief_summary>
	<brief_title>Adalimumab Uveitis Refractory Conventional Therapy ( ADUR Trial )</brief_title>
	<detailed_description>TNF alpha Inhibitors like Infliximab Etanercept effective treat rheumatologic disease . They use treat severe uveitis several group , Suhler coworkers publish large series 2005 . Adalimumab , recombinant , full-length immunoglobulin , first member new class TNF antibody compound developed contain exclusively human sequence . The duration therapeutic efficacy TNF antibody , contain non-human sequence , may limit great extent antibody response raise subject time . We want test efficacy safety TNF alpha Inhibitor Adalimumab patient active uveitis despite standard immunosuppressive therapy require systemic corticosteroid &gt; 7,5mg prednisolone .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female patient age 18 old Subjects must meet criterion noninfectious uveitis accord definition SUN work group Uveitis must first diagnose least 6 month ago Persistence active disease ( &gt; 2 flare within 6 month ) progressive deterioration vision ( &lt; 0,6 ) within last 3 month despite immunosuppressive therapy require corticosteroid â‰¥ 7,5 mg prednisone Women childbearing potential practice reliable birth control method throughout study five month last administration Adalimumab Ability comprehend willing give inform consent participation study Able willing selfadminister sc injection assistance suitable person administer sc injection Negative PPD skin test serological test accord official German recommendation tuberculosis testing AND chest Xray within last three month . Treatment latent TB INH must start 4 week prior administration first dose study drug . Participation another clinical trial and/or observation period compete trial Treatment infliximab within last 2 month etanercept within last 3 week Patients intermediary uveitis optic neuritis multiple sclerosis Patients uveitis cause infection Patients optic atrophy , macular scar , cataract , amblyopia corneal scar Patients recurrent episode uveitis , long intermittent phase complete remission without therapy Patients possibly demand vitrectomy cataract surgery within time clinical trial Pregnant nursing woman woman plan pregnancy within 5 month Persistent recurrent infection severe infection require hospitalization iv antibiotic within 30 day , oral antibiotic within 14 day prior enrollment Known opportunistic infection ( herpes zoster ) last 2 month Live vaccination last 30 day History tuberculosis ; histoplasmosis listeriosis Known HIV infection , active hepatitis B C Comorbidities : uncontrolled diabetes , unstable ischemic heart disease , congestive heart failure ( NYHA III , IV ) , active inflammatory bowl disease , recent stroke ( within three month ) , chronic leg ulcer similar condition would put subject risk participation trial Previous diagnosis sign central nervous system demyelinate disease History cancer lymphoproliferative disease successfully completely treat squamous cell basal cell carcinoma skin cervical dysplasia , recurrence within last two year Hemoglobin &lt; 10 g/dl , white blood cell count &lt; 3.0x109/l , platelet count &lt; 100x109/l , creatinine level &gt; 1.5 mg/dl , liver enzymes &gt; 1.5 time normal alkaline phosphatase &gt; 3 time normal Clinical examination show significant abnormality clinical relevance Current evidence significant abuse drug Psychiatric disease/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>TNF alpha</keyword>
</DOC>